AVALANCHE BIOTECHNOLOGIES, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • May 12th, 2016 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Carlo Russo (“Executive”) and Avalanche Biotechnologies, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).
January 29, 2016 Carlo Russo, M.D. Re: Employment Terms for Executive Vice President and Chief Medical Officer Dear Carlo,Employee Confidentiality and Invention Assignment Agreement • May 12th, 2016 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
In connection with the acquisition (the “Acquisition”) of all outstanding shares of Annapurna Therapeutics SAS (the “Target”) by Avalanche Biotechnologies, Inc. (the “Company”), this letter agreement (the “Agreement”) memorializes the employment terms for your employment with the Company in the position of Executive Vice President and Chief Medical Officer of the Company. These terms will become effective on the closing of the Acquisition (the “Closing Date”). In the event the Acquisition is not consummated, this Agreement shall be of no force or effect. Your first day of work as Executive Vice President and Chief Medical Officer will be the Closing Date.
AVALANCHE BIOTECHNOLOGIES, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • May 12th, 2016 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of May 11, 2016, by and among Avalanche Biotechnologies, Inc., a Delaware corporation (the “Company”) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
